Syncom Formulations (India) Ltd Financials
Company Logo

Syncom Formulations (India) Ltd Financial Statement

Syncom Formulations (India) Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue88.14
Operating Expense76.36
Net Profit7.63
Net Profit Margin8.66
Earning Per Share0.11
EBIDTA11.76
Effective Tax Rate20.71

Syncom Formulations (India) Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual258.36
Operating Expenses Annual230.51
Operating Profit Annual40.93
Interest Annual4.45
Depreciation4.72
Net Profit Annual23.62
Tax Annual8.14

Syncom Formulations (India) Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.83
Cash Flow from Operations-5.94
Cash Flow from Investing83.83
Cash Flow from Financing-15.37
Cash Flow at the End63.35

Syncom Formulations (India) Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)15.94
PBIT Margin (%)14.11
PBT Margin (%)11.11
Net PROFIT Margin (%)9.14
Return On Networth / Equity (%)8.71
Return On Networth /Employed (%)10.32
Return On Assets (%)6.67
Total Debt / Equity (X)0.29
Asset Turnover Ratio (%)0.73

Syncom Formulations (India) Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Fixed Assets Annual43.40
Total Current Assets Annual180.77
Non Current Assets Annual196.17
Total Shareholders Funds Annual256.01
Total Assets Annual376.94

Syncom Formulations (India) Ltd Earning Calls

EPS (INR)

Expected

0.08

Reported

0.11

Surprise

37.50%

Mar 2024

EPS beaten by 37.50%

Dec 2023

EPS beaten by 25.00%

Sep 2023

EPS beaten by 28.57%

Get Your FAQs Right

As of Nov 5, 2024, Syncom Formulations (India) Ltd has a market capitalization of 1,050.92 Cr. Value Research classifies it as a Small-Cap company.
Yes, Syncom Formulations (India) Ltd is debt-free with a debt-to-equity ratio of 0.25.
In FY 2023 , Syncom Formulations (India) Ltd recorded a total revenue of approximately 258.36 Cr marking a significant milestone in the company's financial performance.
Syncom Formulations (India) Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.1% annually, respectively..
Syncom Formulations (India) Ltd's current PE ratio is 44.49.
Syncom Formulations (India) Ltd's ROCE averaged 9.6% from the FY ending March 2022 to 2024, with a median of 10.0%. It peaked at 10.1% in March 2024, reflecting strong capital efficiency over the period..
Syncom Formulations (India) Ltd's latest EBIT is Rs. 36.21 Cr, surpassing the average EBIT of Rs. 31.34 Cr over the 5 years..